Literature DB >> 19133317

The neuroprotective effects of NGF combined with GM1 on injured spinal cord neurons in vitro.

Fei Huang1, Xifeng Dong, Luping Zhang, Xuejun Zhang, Dongmei Zhao, Xianyong Bai, Zhenzhong Li.   

Abstract

Monosialoganglioside (GM1) has been considered to have a neurotrophic factor-like activity. Nerve growth factor (NGF), a member of the neurotrophin family, is essential for neuronal survival, differentiation and maturation. The aim of the present study was to investigate whether co-administration of GM1 and NGF reverses glutamate (Glu) neurotoxicity in primary cultured rat embryonic spinal cord neurons. Spinal cord neurons were exposed to Glu (2 mmol/l), Glu (2 mmol/l) plus GM1 (10 mg/ml), Glu (2 mmol/l) plus NGF (10 ng/ml), Glu (2 mmol/l) plus GM1 (5 mg/ml) and NGF (5 ng/ml) and then processed for detecting intracellular concentrations of Ca2+([Ca2+]i) by confocal laser scanning microscopy and growth associated protein 43 (GAP43) mRNA by RT-PCR. The fluorescent intensity in Glu plus GM1 and NGF incubated neurons was the lowest as compared with that in other groups. The expression of GAP43 mRNA in Glu plus GM1 and NGF incubated neurons was the highest as compared with that in other groups. These results implicated that GM1 and NGF have synergistic neuroprotective effects on spinal cord neurons with excitotoxicity induced by Glu in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19133317     DOI: 10.1016/j.brainresbull.2008.12.007

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  5 in total

Review 1.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

2.  Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase.

Authors:  Alexandre Henriques; Vincent Croixmarie; David A Priestman; Angela Rosenbohm; Sylvie Dirrig-Grosch; Eleonora D'Ambra; Mylene Huebecker; Ghulam Hussain; Claire Boursier-Neyret; Andoni Echaniz-Laguna; Albert C Ludolph; Frances M Platt; Bernard Walther; Michael Spedding; Jean-Philippe Loeffler; Jose-Luis Gonzalez De Aguilar
Journal:  Hum Mol Genet       Date:  2015-10-19       Impact factor: 6.150

3.  Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.

Authors:  De-Shen Wang; Zhi-Qiang Wang; Gong Chen; Jie-Wen Peng; Wei Wang; Yan-Hong Deng; Feng-Hua Wang; Jian-Wei Zhang; Han-Lin Liang; Fen Feng; Chuan-Bo Xie; Chao Ren; Ying Jin; Si-Mei Shi; Wen-Hua Fan; Zhen-Hai Lu; Pei-Rong Ding; Feng Wang; Rui-Hua Xu; Yu-Hong Li
Journal:  Cancer Med       Date:  2019-11-13       Impact factor: 4.452

4.  Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.

Authors:  Yanyun Zhu; Junlan Yang; Shunchang Jiao; Tiefeng Ji
Journal:  World J Surg Oncol       Date:  2013-01-25       Impact factor: 2.754

5.  Neurotrophic effects of GM1 ganglioside, NGF, and FGF2 on canine dorsal root ganglia neurons in vitro.

Authors:  S Schwarz; A Lehmbecker; W Tongtako; K Hahn; Y Wang; F Felmy; I Zdora; G Brogden; K Branitzki-Heinemann; M von Köckritz-Blickwede; W Baumgärtner; I Gerhauser
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.